ALLO — Allogene Therapeutics, Inc. stock price, charts and financials

QT78Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. (NASDAQ: ALLO) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
2.10
+0.09+4.48%
OverviewShort InterestFilings
ALLOQT78Allogene Therapeutics, Inc.·NASDAQ
2.10+4.48%

Latest SEC Filings

Form category
Filing Date ▾FormDescriptionFilingDocument
Aug 07, 2026SC 13G/ABeneficial ownership statement (passive, amended)
Aug 07, 2026SC 13GBeneficial ownership statement (passive)
Jul 06, 20264Statement of changes in beneficial ownership
Jun 23, 20264Statement of changes in beneficial ownership
Jun 23, 20264Statement of changes in beneficial ownership
Jun 23, 20264Statement of changes in beneficial ownership
Jun 23, 20264Statement of changes in beneficial ownership
Jun 23, 20264Statement of changes in beneficial ownership
Jun 23, 20264Statement of changes in beneficial ownership
Jun 23, 20264Statement of changes in beneficial ownership
Jun 22, 2026424B5Prospectus
Jun 22, 20268-KCurrent report
May 28, 2026DEFA14AAdditional proxy soliciting materials
May 28, 20268-KCurrent report
May 21, 2026DEFA14AAdditional proxy soliciting materials
May 15, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 15, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 13, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 13, 20268-KCurrent report
May 13, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 13, 202610-QQuarterly report
Apr 30, 2026ARSAnnual report to shareholders
Apr 30, 2026DEFA14AAdditional proxy soliciting materials
Apr 30, 2026DEF 14ADefinitive proxy statement
Apr 23, 2026SC 13GBeneficial ownership statement (passive)
#1 / 25 of 320
Page
▼
/ 13